Core-B Clinical Services and Diagnostics

拟建中心的临床服务和诊断核心是一种独特的资源， 围绕第一集的招募、定性和严格的诊断评估进行组织， 抗精神病药物-幼稚精神分裂症和非精神分裂症精神病受试者，以及健康对照，以及 获取尸检中使用的受试者的临床数据和诊断。临床研究 在拟建的中心将使用多模式电生理方法、功能神经成像 (功能磁共振成像)方法(项目5-Phillips)和一种新的PET方法(项目6-Mathis)来检验假设 关于皮质神经元网络活动、GABA神经传递和 精神分裂症患者的信息处理缺陷。核心整合和协调招聘和 对拟建中心内的项目以及其他资助的协作项目进行主题评估 确保受试者有效和富有成效地参与的项目，最低限度地冗余 活动。核心教职员工的临床和诊断专业知识也被用于定性 项目1中使用了尸检脑标本的个人的临床研究诊断- 刘易斯。临床服务和诊断核心的基础设施也是一种教育 青年研究人员有机会制定种子提案，以解决与 精神分裂症的病理生理学，并作为一种手段教育执业的临床医生，学生和 公众对精神分裂症研究的进展。

The Clinical Services and Diagnostics Core of the proposed Center represents a unique resource that is organized around the recruitment, characterization and rigorous diagnostic evaluation of first-episode, antipsychotic-naive schizophrenia and non-schizophrenia psychotic subjects, and healthy controls, and the acquisition of clinical data and diagnoses of subjects used in postmortem studies. Clinical research studies conducted in the proposed Center will use multimodal electrophysiological methods, functional neuroimaging (fMRI) approaches (Project 5-Phillips), and a novel PET method (Project 6-Mathis) to test hypotheses regarding the relationships between cortical neuronal network activity, GABA neurotransmission and information processing deficits in schizophrenia. The Core integrates and coordinates the recruitment and assessment of subjects across projects within the proposed Center as well as for other funded collaborative projects to ensure that subjects are efficiently and productively engaged with a minimum redundancy of activities. The clinical and diagnostic expertise of Core faculty and staff is also utilized in the characterization of the clinical research diagnoses of individuals whose post-mortem brain specimens are used in Project 1- Lewis. The infrastructure of the Clinical Services and Diagnostics Core also serves as an educational opportunity for young investigators to develop seed proposals to address questions relating to the pathophysiology of schizophrenia, and as a means to educate the practicing clinicians, students, and the general public about advances in schizophrenia research.